Carcinoid neuroendocrine cancers are relatively rare malignancies distinguished
small, slow growing tumors which affect the neuroendocrine system. These
typically originate in the gastro-intestinal tract, but sometimes arise in the lungs or
other organs. Incidence is around 4 persons in 100,000 - but in many parts of the
world the disease is under-diagnosed.
A variety of excellent treatment options are available, most of which target specific
peptide receptors on the tumor cells. Among the best known treatments are
Octreotide, Lanreotide and similar hormonal treatments, which provide
relief and have anti-proliferative benefits. Other newer therapies use these drugs
combination with radioisotopes, as a targeted radiation treatment.
This is an unmoderated forum for patients, caregivers, researchers,
and physicians to discuss the clinical and nonclinical aspects of Carcinoid
neuroendocrine cancer. Please refer to the house rules before you
any commercial, copyrighted, political or off-topic material.
To access this forum, click on the "Subscribe or Unsubscribe" link, enter a
name (or nickname), provide a valid email address, select the type of subscription
(Index HTML format is recommended), submit the form and acknowledge the
sent to you for verification. For more information, click on the 'help' button (a
green question mark in the upper-right corner of this page), or
send email to the list owners.
Quick links: [house
rules], [settings], [email list managers], [CCF archives] and [unsubscribe]